Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-β2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis

Clinical Laboratory

Volumn 49, Issue 11-12, 2003, Pages 625-636

  Shaarawy, Mohamed ^a,b   Zaki, Sameh ^a   Sheiba, Mamdouh ^a   El Minawi, Ahmad M ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b NONE   (Egypt)

Author keywords

Alendronate; Alfacalcidol; Antiresorptive therapy; Bone turnover markers; Calcitonin; HRT; IL 11; Interleukin 11; Osteoporosis; TGF ; Transforming growth factor 2

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CALCITONIN; CALCIUM CARBONATE; COLLAGEN TYPE 1; CYTOKINE; DEOXYPYRIDINOLINE; ESTRADIOL; INTERLEUKIN 11; NORETHISTERONE; NORETHISTERONE ACETATE; OSTEOCALCIN; SALCATONIN; TRANSFORMING GROWTH FACTOR BETA2;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOCLAST; OSTEOID; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; URINALYSIS;

ADULT; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; INTERLEUKIN-11; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

EID: 0345169760     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Riggs BL, Wahner HW, Seeman, et al. (1982) Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 70: 816-823.
2. Shaarawy M, El-Mallah S, Hassan H, Aref A (1997) Choice of reliable biochemical markers for assessment of bone remodeling in postmenopausal osteoporosis. Menopause 4(4): 212-218.
3. Paraviainen M, Kuronen I, Kokko H, Lakaniemi M, Savolaiven K, Mononen I (1994) Two site enzyme immunoassay for measuring intact human osteocalcin in serum. J Bone Mineral Res. 9: 347-354.
4. Seydin SM, Kung VT, Daniloff KN et al (1993) Immunoassay for urinary pyridinoline. The new biomarker of bone resorption. J Bone Mineral Res. 8: 635-641.
5. Strong DD, Beacher AL, Wergidal JE, Linkhart TA (1991) Insulin-like growth factor-2 and transforming growth factor b regulate collagen expression in human osteoblast-like cells in vitro. J Bone Mineral Res. 6: 15-23.
6. Cannalis E, McCarthy T, Cenrella M (1988). Growth factors and the regulation of bone remodeling. J Clin Invest. 81: 271-277.
7. Hammerman MR (1987) Insulin-like growth factors and aging. Clin Endocrinol Metab 16: 995-1011.
8. Pfeilshifter J, Dicl I, Pilz U, Brunotte K, Naumann A, Ziegler R (1993) Mitogenic responsiveness of human bone cells in-vitro to hormones and growth factors decreases with age. J Bone Mineral Res. 8: 707-717.
9. Delmas PD, Wilson DM, Mann K, Riggs BL (1983) Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 57: 1028-30.
10. Lorenzo JA (1992) The role of cytokines in the regulation of local bone resorption. Crit Rev Immunol. 11: 195-213.
11. Raisz LG (1999) Physiology and pathophysiology of bone remodeling. Clin Chem 45 (8B). 1353-1358.
12. Sakou T (1998) Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 22: 591-603.
13. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazano K, Kato S (1999) Convergence of transforming growth factor β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283: 1317-1321.
14. Jones SI, Taylor ML, Macannachie E, Mundy GR, Boyde A (1990) TGFβ can directly activate mature osteoclast. Calcif Tiss Int. 46: 149-153.
15. Bonewald LE, Mundy GR (1990) Role of transforming growth factor β in bone remodeling, a review. Clin Orthop 250: 261-265.
16. Morinaga Y, Futita N, Ohishi R, Tsurout T (1997) Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor β and tumor cell factors. Int J Cancer 71(3): 422-428.
17. Hill PA, Tamber A, Papaioanou S, Meikle MC (1998) The cellular action of interleukin-11 on bone resorption in vitro. Endocrinol 139(4): 564-572.
18. Horowitz MC (1993) Cytokines and estrogen in bone: anti-osteoporotic effects. Science. 260: 626-627.
19. Grainger DJ, Percival J, Chiano M, Spector TD (1999) The role of serum TGF-beta isoforms as potential markers of osteoporosis. Osteoporosis Int. 9(5): 398-404.
20. Roberts JM, Taylor RM, Musci JT (1991) Endothelial cell activation as pathogenic factor in preeclampsia. Semin Perinatal 15: 86-93.
21. Erlebacher A, Filvaroff EH, Ye JQ, Derynck R (1998) Osteoblastic responses to TGFβ during bone remodeling. Mol Biol Cell. 9(7): 1903-1918.
22. Girasole G, Passeri G, Jilka Manolagas SC (1994) Interleukin-11, a new cytokine critical for osteoclast development. J Clin Invest. 93: 1312-1318.
23. 3 in primary murine bone marrow cultures. Pharmacol Toxicol. 82(5): 223-229.
24. Rosen CJ, Chesnut CH, Mallinak NJ (1997) The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone-replacement or calcium supplementation. J Clin Endocrinol Metab. 82: 1904-1910.
25. Ravn P, Christensen JO, Bauman M, Clemmesen B (1998) Changes in biochemical markers and bone mass after withdrawal of ibandronate treament: prediction of bone mass changes during treatment. Bone 22; 559-564.
26. Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, Wark JD (1996) Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab. 81: 3366-3371.
27. Prestwood KM, Thompson DL, Kenny AM, Siebel MJ, Pileam CC, Raisz LG (1999) Low dose estrogen and calcium have an additive effect on bone resorption in older women. J Clin Endocrinol Metab 48: 179-183.
28. Fleisch H (1994) The use of bisphosphonates in osteoporosis. Br J Clin Pract 48: 323-326.
29. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yales AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84: 2363-2368.
30. Chambers JJ, Magnus CJ (1982) Calcitonin causes contraction of mature multinucleated osteoclast. J Pathol 136: 27-32.
31. Gruber HE, Ivery JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesut CH (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 3(4): 295-303.
32. David P., Torben BH, Chris KR, Cirsten W (1996) Prevention and treatment of vitamin D related diseases. Canadian Medical Ass J. 155:955-961.
33. Garnero P, Somay-Rendu E, Chapuy MC, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Mineral Res. 11: 337-349.
34. Dechant KC, Groa KL (1994) Alfacalcidol; a review of its use in the treatment of postmenoapusal osteoporosis and its potential in corticosteroid-induced osteoporosis. Drug Aging 5: 300-317.
35. Dawson-Hughes B, Harris S, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 337: 670-676.